These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29579325)

  • 1. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
    Pishvaian MJ; Slack RS; Jiang W; He AR; Hwang JJ; Hankin A; Dorsch-Vogel K; Kukadiya D; Weiner LM; Marshall JL; Brody JR
    Cancer; 2018 Jun; 124(11):2337-2346. PubMed ID: 29579325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
    Gojo I; Beumer JH; Pratz KW; McDevitt MA; Baer MR; Blackford AL; Smith BD; Gore SD; Carraway HE; Showel MM; Levis MJ; Dezern AE; Gladstone DE; Ji JJ; Wang L; Kinders RJ; Pouquet M; Ali-Walbi I; Rudek MA; Poh W; Herman JG; Karnitz LM; Kaufmann SH; Chen A; Karp JE
    Clin Cancer Res; 2017 Feb; 23(3):697-706. PubMed ID: 27503200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
    Hussain M; Carducci MA; Slovin S; Cetnar J; Qian J; McKeegan EM; Refici-Buhr M; Chyla B; Shepherd SP; Giranda VL; Alumkal JJ
    Invest New Drugs; 2014 Oct; 32(5):904-12. PubMed ID: 24764124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
    Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
    Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
    Morano F; Corallo S; Niger M; Barault L; Milione M; Berenato R; Moretto R; Randon G; Antista M; Belfiore A; Raimondi A; Nichetti F; Martinetti A; Battaglia L; Perrone F; Pruneri G; Falcone A; Di Bartolomeo M; de Braud F; Di Nicolantonio F; Cremolini C; Pietrantonio F
    Ann Oncol; 2018 Aug; 29(8):1800-1806. PubMed ID: 29860358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
    Pietanza MC; Waqar SN; Krug LM; Dowlati A; Hann CL; Chiappori A; Owonikoko TK; Woo KM; Cardnell RJ; Fujimoto J; Long L; Diao L; Wang J; Bensman Y; Hurtado B; de Groot P; Sulman EP; Wistuba II; Chen A; Fleisher M; Heymach JV; Kris MG; Rudin CM; Byers LA
    J Clin Oncol; 2018 Aug; 36(23):2386-2394. PubMed ID: 29906251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
    Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S
    Ann Oncol; 2018 Jan; 29(1):154-161. PubMed ID: 29045554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
    Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
    Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF
    Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
    Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
    Wahner Hendrickson AE; Menefee ME; Hartmann LC; Long HJ; Northfelt DW; Reid JM; Boakye-Agyeman F; Kayode O; Flatten KS; Harrell MI; Swisher EM; Poirier GG; Satele D; Allred J; Lensing JL; Chen A; Ji J; Zang Y; Erlichman C; Haluska P; Kaufmann SH
    Clin Cancer Res; 2018 Feb; 24(4):744-752. PubMed ID: 29138343
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
    LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
    Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.
    Nuthalapati S; Munasinghe W; Giranda V; Xiong H
    Clin Pharmacokinet; 2018 Jan; 57(1):51-58. PubMed ID: 28497258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
    Singh R; Mehrotra S; Gopalakrishnan M; Gojo I; Karp JE; Greer JM; Chen A; Piekarz R; Kiesel BF; Gobburu J; Rudek MA; Beumer JH;
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):319-328. PubMed ID: 30456480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors.
    Stradella A; Johnson M; Goel S; Park H; Lakhani N; Arkenau HT; Galsky MD; Calvo E; Baz V; Moreno V; Saavedra O; Luen SJ; Mu S; Wan Q; Chang V; Zhang W; Barve M
    Cancer Med; 2024 Jul; 13(13):e7385. PubMed ID: 38970256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
    Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
    Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
    Kummar S; Wade JL; Oza AM; Sullivan D; Chen AP; Gandara DR; Ji J; Kinders RJ; Wang L; Allen D; Coyne GO; Steinberg SM; Doroshow JH
    Invest New Drugs; 2016 Jun; 34(3):355-63. PubMed ID: 26996385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
    Villalona-Calero MA; Duan W; Zhao W; Shilo K; Schaaf LJ; Thurmond J; Westman JA; Marshall J; Xiaobai L; Ji J; Rose J; Lustberg M; Bekaii-Saab T; Chen A; Timmers C
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26848151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
    Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
    Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
    Xu J; Keenan TE; Overmoyer B; Tung NM; Gelman RS; Habin K; Garber JE; Ellisen LW; Winer EP; Goss PE; Yeap BY; Chabner BA; Isakoff SJ
    Breast Cancer Res Treat; 2021 Oct; 189(3):641-651. PubMed ID: 34417675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.